Moderna and Merck to Develop Together a Cancer Vaccine for High-risk Melanoma Patients


Moderna and Merck declared that they would work together to create and market a cancer vaccine that is customized for every patient.

In a phase two trial, the vaccine from Moderna, which is based on their messenger RNA technology, is being examined in conjunction with Merck’s Keytruda to treat patients with high-risk melanoma, the most lethal type of skin cancer. The businesses anticipate disclosing information in this year’s fourth quarter.

After the news was announced, the stock of Moderna surged 16% in morning trading before losing some of that gain. In afternoon trade, the company’s shares increased by roughly 10%.

Keytruda is the largest drug sold by Merck. It accounted for 35% of all sales for the business in the second quarter. The Food and Drug Administration has given it the go-ahead to treat a variety of cancers.

The contracts were initially signed in 2016, but Merck is now exercising its option by paying Moderna $250 million. Merck will work with other companies to develop and market the product. Each company will split both expenses and earnings evenly.

No Comments Yet

Comments are closed


CIO Look is Global business authority platform where you can explore the perspective of Entrepreneurs, business owners, and innovators who drive business around the globe. CIOLook has unvaryingly been at the front line for its honesty and genuineness acquiring acknowledgment from Business pioneers universally. It features best business hones inferred by individuals, organizations, and industry divisions around the globe…. Read More

Follow us